Opinion|Videos|July 8, 2024
AE Management With IO-TKI and IO-IO in RCC
Author(s)Martin H. Voss, MD
Martin H. Voss, MD, outlines adverse events encountered with different IO-TKI and IO-IO combination regimens in RCC and discusses the importance of open communication with patients.
Advertisement
Episodes in this series
Video content above is prompted by the following question:
- What are the most significant adverse events seen with different IO-TKI and IO-IO combination regimens used in renal cell carcinoma (RCC)?
Advertisement
Related to this article
Oncologists weigh second-line options after IO/TKI failure in metastatic ccRCC, highlighting tolerability, mechanism shifts, and belzutifan’s broader role.
The FDA has approved Omcazio, a capsule-based formulation of cabozantinib as a laurylsulfate salt, that demonstrated bioequivalence to the existing tablet.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Imlunestrant Plus Abemaciclib in ESR1-Mutated Breast Cancer
2
Data Increasingly Favor BCMA-Directed Therapy For Early-Relapse Myeloma
3
Sub-Q Amivantamab and Supportive Care Minimize Discontinuation in EGFR+ NSCLC
4
Daraxonrasib Combo Receives FDA Breakthrough Status in First-Line PDAC
5